Microbot Medical (NASDAQ: MBOT) reported Q1 EPS of $-0.050, $0.03 better than the analyst estimate of $-0.083.
Revenue for the quarter came in at $105K versus the consensus estimate of $300K.
Microbot Medical's stock closed at $1.81, down -24.900% over the last 3 months and -36.040% over the last 12 months.
There were 1 positive EPS revision and 0 negative revisions in the last 90 days.
According to Bond.az, Microbot Medical's Financial Health score is "fair performance".











